Adge Contact Leadership News Therapeutic Focus Assets
Addressing Significant Unmet Medical Needs
ASSET
Asset Summary
  • A clinical stage orally available small molecule with best-in-class safety
  • Mechanism of action supports application in diseases with major unmet medical needs
  • Focus on rare diseases leveraging orphan drug development (ODD) path
THERAPEUTIC
Therapeutic Focus
Osteogenesis Imperfecta (Bone)
Rett Syndrome (Neurological)
NEWS
News
April 25, 2022 16:00 PDT
Adge Pharmaceuticals partners with Cyan Bio of Korea to advance treatments for rare pediatric diseases in Asian countries.
April 12, 2022 16:00 PDT
Adge Pharmaceuticals advances its rare disease programs, attends ASCEND 2022 Rett Syndrome National Summit.
March 22, 2022 7:00 PDT
Adge Pharmaceuticals secures license to evaluate two new programs in rare pediatric diseases.
Leadership
Leadership
Kalev Kask PhD
CEO
Dr. Kalev Kask is the founder and Chief Executive Officer of Adge. Before Adge he led the growth of EGeen International into a global clinical research organization as its founding Chief Executive Officer. He is an accomplished dealmaker with an extensive scientific command and commercial acumen. Dr. Kask completed his postgraduate training at Stockholm University, Stanford University and Max-Planck Institute for Medical Research in Heidelberg. Dr. Kask is an inventor on multiple patents and has authored numerous scientific publications.
PIPELINE
Clinical Pipeline
pipeline
RETT SYNDROME
Rett Syndrome
  • Rare pediatric neurological disorder caused by a mutation in the MECP2 gene on the X-chromosome
  • Only affects females (boys die prenatally) leading to deficient cognitive, sensory, motor and autonomic functions.
  • 20,000 RTT patients in the US and 20,000 in Europe
  • No treatment available
OSTEOGENESIS
Osteogenesis Imperfecta
  • Genetic disorder of bone formation characterized by bone fragility and low bone mass
  • Mutations in type I collagen, collagen-associated proteins and other genes regulating osteoblast activity and signaling
  • US prevalence of 20,000 to 50,000
  • No treatment available
  • New bone formation is required for success in osteogenesis imperfecta
E-Mail: info@adgepharm.com 938 Rich Place Mountain View, CA 94040 USA
Copyright © Adge Pharmaceuticals 2022